- Home
- RNP vs IMTX Comparison
RNP vs IMTX Comparison
Compare RNP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNP
- IMTX
- Stock Information
- Founded
- RNP 2003
- IMTX N/A
- Country
- RNP United States
- IMTX Germany
- Employees
- RNP N/A
- IMTX N/A
- Industry
- RNP Investment Managers
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNP Finance
- IMTX Health Care
- Exchange
- RNP Nasdaq
- IMTX Nasdaq
- Market Cap
- RNP 1.0B
- IMTX 1.1B
- IPO Year
- RNP N/A
- IMTX N/A
- Fundamental
- Price
- RNP $20.17
- IMTX $10.41
- Analyst Decision
- RNP
- IMTX Strong Buy
- Analyst Count
- RNP 0
- IMTX 4
- Target Price
- RNP N/A
- IMTX $17.33
- AVG Volume (30 Days)
- RNP 117.6K
- IMTX 620.7K
- Earning Date
- RNP 01-01-0001
- IMTX 11-17-2025
- Dividend Yield
- RNP 7.94%
- IMTX N/A
- EPS Growth
- RNP N/A
- IMTX N/A
- EPS
- RNP N/A
- IMTX N/A
- Revenue
- RNP N/A
- IMTX $99,445,031.00
- Revenue This Year
- RNP N/A
- IMTX N/A
- Revenue Next Year
- RNP N/A
- IMTX $13.52
- P/E Ratio
- RNP N/A
- IMTX N/A
- Revenue Growth
- RNP N/A
- IMTX N/A
- 52 Week Low
- RNP $15.52
- IMTX $3.30
- 52 Week High
- RNP $21.27
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- RNP 25.94
- IMTX 57.37
- Support Level
- RNP $20.75
- IMTX $9.14
- Resistance Level
- RNP $21.33
- IMTX $10.86
- Average True Range (ATR)
- RNP 0.28
- IMTX 0.72
- MACD
- RNP -0.08
- IMTX 0.00
- Stochastic Oscillator
- RNP 0.00
- IMTX 82.81
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.